Everolimus (rad001) , afinitor® (DrugBank: Everolimus)
9 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
34 | 神経線維腫症 | 1 |
67 | 多発性嚢胞腎 | 0 |
89 | リンパ脈管筋腫症 | 0 |
96 | クローン病 | 0 |
137 | 限局性皮質異形成 | 0 |
157 | スタージ・ウェーバー症候群 | 0 |
158 | 結節性硬化症 | 0 |
228 | 閉塞性細気管支炎 | 0 |
277 | リンパ管腫症/ゴーハム病 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01419639 (ClinicalTrials.gov) | October 2011 | 17/8/2011 | Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 | Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 | Neurofibromatosis Type II | Drug: Everolimus (RAD001) , Afinitor® | New York University School of Medicine | Novartis Pharmaceuticals;The Children's Tumor Foundation | Completed | 3 Years | N/A | All | 10 | Phase 2 | United States |